Blood clot row: European Commission to not renew AstraZeneca, J&J COVID-19 vaccine contracts, says report

WION Web Team
New Delhi, India Published: Apr 14, 2021, 01:18 PM(IST)

A vial of AstraZeneca Covid-19 vaccine is pictured at a vaccination centre Photograph:( AFP )

Story highlights

European Commission is in agreement with the leaders of many EU countries to not renew the vaccine contracts for companies that have produced viral vector vaccines

The European Commission has decided against renewing coronavirus vaccine contracts next year with AstraZeneca and Johnson & Johnson in view of the recent concerns surrounding the jabs made by the companies.

Italian newspaper La Stampa on Wednesday revealed the big move, citing a source in the Italian Health Ministry. According to the newspaper, the EU Commission is in agreement with the leaders of many EU countries to not renew the vaccine contracts for companies that have produced viral vector vaccines.

The contracts are valid for 2021 and will not be renewed for 2022. The EU is reportedly shifting is focus to vaccines that have been developed using the mRNA (messenger RNA) technology - the ones made by Pfizer-BioNTech and Moderna.

Also read: Botswana is probing link between two deaths and AstraZeneca Covid shots

An EU official told Reuters on Tuesday that they are awaiting a clarification from Johnson & Johnson about the “completely unexpected” delay in delivery of vaccines to the bloc which has been hit hard.

Also read: Australia orders more alternatives for AstraZeneca vaccine setting back its rollout

Both the vaccines developed by AstraZeneca and Johnson & Johnson have come under the scrutiny of health regulators after instances of blood clots were reported. Even though very rare, the clots have led to deaths, prompting many countries to halt the usage of these vaccines.

(With inputs from agencies)

Read in App